Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

471 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes.
Nagasaki J, Inozume T, Sax N, Ariyasu R, Ishikawa M, Yamashita K, Kawazu M, Ueno T, Irie T, Tanji E, Morinaga T, Honobe A, Ohnuma T, Yoshino M, Iwata T, Kawase K, Sasaki K, Hanazawa T, Kochin V, Kawamura T, Matsue H, Hino M, Mano H, Suzuki Y, Nishikawa H, Togashi Y. Nagasaki J, et al. Among authors: ohnuma t. Cell Rep. 2022 Feb 1;38(5):110331. doi: 10.1016/j.celrep.2022.110331. Cell Rep. 2022. PMID: 35108529 Free article.
Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti-PD-1 Therapy.
Inozume T, Yaguchi T, Ariyasu R, Togashi Y, Ohnuma T, Honobe A, Nishikawa H, Kawakami Y, Kawamura T. Inozume T, et al. Among authors: ohnuma t. J Invest Dermatol. 2019 Jul;139(7):1490-1496. doi: 10.1016/j.jid.2019.01.007. Epub 2019 Jan 23. J Invest Dermatol. 2019. PMID: 30684558 Free article.
TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S, Inozume T, Kawazu M, Ueno T, Nagasaki J, Tanji E, Honobe A, Ohnuma T, Kawamura T, Umeda Y, Nakamura Y, Kawasaki T, Kiniwa Y, Yamasaki O, Fukushima S, Ikehara Y, Mano H, Suzuki Y, Nishikawa H, Matsue H, Togashi Y. Kawashima S, et al. Among authors: ohnuma t. J Immunother Cancer. 2021 Nov;9(11):e003134. doi: 10.1136/jitc-2021-003134. J Immunother Cancer. 2021. PMID: 34795004 Free PMC article.
Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration.
Morinaga T, Inozume T, Kawazu M, Ueda Y, Sax N, Yamashita K, Kawashima S, Nagasaki J, Ueno T, Lin J, Ohara Y, Kuwata T, Yukami H, Kawazoe A, Shitara K, Honobe-Tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Kawahara Y, Nakamura Y, Kiniwa Y, Morita A, Ichihara E, Kiura K, Enokida T, Tahara M, Hasegawa Y, Mano H, Suzuki Y, Nishikawa H, Togashi Y. Morinaga T, et al. Among authors: ohnuma t. Cancer Res Commun. 2022 Jul 28;2(7):739-753. doi: 10.1158/2767-9764.CRC-22-0050. eCollection 2022 Jul. Cancer Res Commun. 2022. PMID: 36923281 Free PMC article.
471 results